Indian pharmaceutical firm Zydus Cadila revealed that it has received the final approval from the US Food and Drug Administration to market its anti-diabetic drug, Pioglitazone HCI, in the American market.
Zydus announced that it has received approval to market Pioglitazone HCI tablets in 15 mg, 30 mg and 45 mg strengths. The company added that sales for Pioglitazone HCI tablets was estimated at $2 billion in 2012, according to data from IMS.
AdvertisementThe company has so far filed over 170 Abbreviated New Drug Applications (ANDA) since 2003-04 and has so far received 75 approvals, including for the sale of oral tablets of Ultracet.
P Relationship Anxieties may Lower Immunity and Increase Risk to Illness: Study 'One Billion Rising' Campaign Brings Together Social Activists For The Cause Of Gender Sensitization M
You May Also Like